BeyondSpring (BYSI) Current Assets (2015 - 2026)
BeyondSpring (BYSI) posted Current Assets of $13.5 million for Q1 2026, down 35.33% sequentially from $20.9 million in Q4 2025, and down 57.17% YoY from $31.5 million in Q1 2025.
BeyondSpring (BYSI) Current Assets (2015 - 2026) Analysis & Trends
BeyondSpring has reported Current Assets for 12 years, with the latest figure at $13.5 million in Q1 2026.
- Quarterly Current Assets fell 57.17% year-over-year to $13.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.5 million (down 57.17% YoY) and the FY2025 annual result came in at $20.9 million, down 26.93% from the prior year.
- Current Assets slipped to $13.5 million in Q1 2026 per BYSI's latest filing, from $20.9 million in the prior quarter.
- Over five years, Current Assets peaked at $55.7 million in Q2 2022 and troughed at $13.5 million in Q1 2026.
- A 5-year average of $27.1 million and a median of $25.7 million in 2025 frame the typical range for Current Assets.
- The sharpest annual moves came in 2025 and 2026: Current Assets jumped 72.34% in 2025, then tumbled 57.17% in 2026.
- Over 5 years, Current Assets stood at $38.5 million in 2022, then sank by 52.19% to $18.4 million in 2023, then surged by 55.15% to $28.6 million in 2024, then declined by 26.93% to $20.9 million in 2025, then sank by 35.33% to $13.5 million in 2026.
- According to Business Quant data, Current Assets over the past three periods registered $13.5 million, $20.9 million, and $24.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.62 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.63 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 1.76 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 18.80 Bn |
| 10 | BeyondSpring | 30.22 Mn | 30.22 Mn | - | 9.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.90 Mn |
| Mar 31, 2026 | 13.50 Mn |
| Dec 31, 2025 | 20.88 Mn |
| Sep 30, 2025 | 24.41 Mn |
| Jun 30, 2025 | 25.71 Mn |
| Mar 31, 2025 | 31.53 Mn |
| Dec 31, 2024 | 28.58 Mn |
| Jun 30, 2024 | 14.92 Mn |
| Dec 31, 2023 | 18.42 Mn |
| Jun 30, 2023 | 25.79 Mn |
| Dec 31, 2022 | 38.52 Mn |
| Jun 30, 2022 | 55.73 Mn |
| Dec 31, 2021 | 75.12 Mn |
| Sep 30, 2021 | 94.67 Mn |
| Jun 30, 2021 | 79.84 Mn |
| Mar 31, 2021 | 94.37 Mn |
| Dec 31, 2020 | 113.40 Mn |
| Sep 30, 2020 | 35.69 Mn |
| Jun 30, 2020 | 42.98 Mn |
| Mar 31, 2020 | 29.75 Mn |